	JRS Pharma announced the expansion its line of excipients for tablet binding and disintegration with a Feb. 28, 2017 press statement about a povidone product line that features Vivapharm PVP (povidone) wet binder, Vivapharm PVP/VA 64 (copovidone) tablet binder, and Vivapharm PVPP (crospovidone) to facilitate disintegration performance.

	The company reports that the excipients are manufactured in a GMP and ISO 9001 compliant/certified production facility and comply with current compendial requirements in the European, US, and Japanese.

	The company reports that it conducts on-site quality checks and final quality control and release in the Analytical Competence Center at the JRS Pharma facilities in Germany.

	The company reports that it conducts on-site quality checks and final quality control and release in the Analytical Competence Center at the JRS Pharma facilities in Germany. The products will be warehoused in the JRS PHARMA central logistics center in Germany and the USA, thus enabling ease and speed of delivery.

Development

Excipients

PharmTech News

Supplier News

PTSM: Pharmaceutical Technology Sourcing and Management-04-05-2017

Excipient manufacturer adds three tablet binding and disintegration products.